HHLR Advisors’s Metagenomi Therapeutics MGX Stock Holding History

HHLR Advisors’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-150,699	Closed	-$205K	–	49
2025 Q1	$205K	Sell	150,699 -627,069	-81%	-$1.49M	0.01%	46
2024 Q4	$2.81M	Hold	777,768	–	–	0.1%	28
2024 Q3	$1.69M	Hold	777,768	–	–	0.04%	37
2024 Q2	$3.17M	Hold	777,768	–	–	0.08%	46
2024 Q1	$8.21M	Buy	+777,768	New	+$8.94M	0.18%	34

Other funds holding MGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SVGI

Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HHLR Advisors's MGX Position: Q2 2025 in Review

HHLR Advisors sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 150,699 shares — an estimated $205K sold.

HHLR Advisors first reported a position in MGX in Q1 2024 and held it in 5 quarters. The position peaked at $8.21M in Q1 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

HHLR Advisors reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
HHLR Advisors sold 150,699 Metagenomi Therapeutics shares in Q2 2025, an estimated $205K.
HHLR Advisors first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 5 quarters.
HHLR Advisors's Metagenomi Therapeutics position peaked at $8.21M in Q1 2024.
69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on HHLR Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.